Skip to content

Total Facet Arthroplasty System®(TFAS®) Clinical Trial

A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness of Total Facet Arthroplasty in the Treatment of Degenerative Spinal Stenosis

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00418197
Enrollment
450
Registered
2007-01-04
Start date
2005-08-31
Completion date
Unknown
Last updated
2009-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leg Pain, Low Back Pain, Lumbar Spinal Stenosis, Spinal Diseases, Spinal Stenosis, Spondylolisthesis

Keywords

spinal stenosis, low back pain, spondylolisthesis, lumbar spinal stenosis, leg pain, spinal diseases

Brief summary

The Archus Total Facet Arthroplasty System® (TFAS®) is a non-fusion spinal implant indicated for treatment of patients with moderate to severe spinal stenosis. TFAS® replaces the diseased facets following surgical removal. TFAS® offers the surgeon new options for treating spinal stenosis patients, enabling a more comprehensive decompression via complete removal of the facets. TFAS® also offers an alternative to rigid spinal fusion fixation enabling intervertebral motion. The clinical trial is intended to demonstrate restoration of stability and sagittal balance to the spine. TFAS® also eliminates the need for painful bone graft harvest from the patient's hip which may be required with fusion procedures.

Interventions

DEVICETotal Facet Arthroplasty System® (TFAS®)

Sponsors

Archus Orthopedics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Degenerative spinal stenosis, central or lateral, at spinal levels L3-L4 or L4-L5 * Skeletally mature male or female between the ages of 50 and 85 years of age inclusive * No greater than Grade I degenerative spondylolisthesis at the index level * Persistent leg symptoms,including pain, numbness, burning or tingling for a minimum duration of six months * Operative candidates with no more than three levels of degenerative lumbar spinal stenosis requiring decompression * Failed to respond to non-operative treatment modalities for a minimum duration of six months

Exclusion criteria

* Male or female less than 50 or greater than 85 years old Grade 2 or higher spondylolisthesis or any retrolisthesis at the index level * More than 3 vertebral levels of degenerative spinal stenosis requiring decompression * More than 1 vertebral level of degenerative spinal stenosis requiring instrumentation * Not available for long term follow-up and interval visits * Prior or concurrently planned lumbar fusion or disc replacement at any level of the lumbar spine * Two or more previous surgeries to the lumbar spine at the same level to be implanted * Is being treated with other devices for the same disorder (e.g. pain control devices) * Active systemic infection or infection at the operating site * Osteoporosis * Known sensitivity to device materials * Has an immunosuppressive disorder * Has a medical condition that may interfere with clinical evaluations * Is obese defined by a patient body mass index greater than 40 * Has significant scoliosis (Cobb \>25°) * Is pregnant or planning to become pregnant within the proposed three year investigation

Design outcomes

Primary

MeasureTime frame
The primary safety and efficacy evaluation endpoints to determine individual patient success are the Zurich Claudication Questionnaire (ZCQ), neurologic status, solid fusion for the control (spinal fusion) group.

Secondary

MeasureTime frame
Visual Analog Scales (VAS) for Leg and Back pain, SF-36 scores, radiographic measurements.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026